• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性结节性痒疹:临床特征与负担。一项欧洲横断面研究。

Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study.

作者信息

Pereira M P, Hoffmann V, Weisshaar E, Wallengren J, Halvorsen J A, Garcovich S, Misery L, Brenaut E, Savk E, Potekaev N, Lvov A, Bobko S, Szepietowski J C, Reich A, Bozek A, Legat F J, Metz M, Streit M, Serra-Baldrich E, Gonçalo M, Storck M, Greiwe I, Nau T, Steinke S, Dugas M, Ständer S, Zeidler C

机构信息

Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.

Occupational Medicine, Department of Dermatology, University of Heidelberg, Heidelberg, Germany.

出版信息

J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2373-2383. doi: 10.1111/jdv.16309. Epub 2020 May 12.

DOI:10.1111/jdv.16309
PMID:32078192
Abstract

BACKGROUND

Chronic nodular prurigo (CNPG) is a condition characterized by chronic itch, a prolonged scratching behaviour and the presence of pruriginous nodules. A comprehensive understanding of this condition, especially regarding its clinical characteristics and impact on quality of life is still lacking.

OBJECTIVES

Aim of this pan-European multicentre cross-sectional study was to establish the clinical profile of CNPG, including its associated burden.

METHODS

Fifteen centres from 12 European countries recruited CNPG patients presenting at the centre or using the centres' own databases. Patients were asked to complete a questionnaire in paper or electronic format. Demography, current co-morbidities, underlying disease, itch intensity, additional sensory symptoms, quality of life, highest burden and emotional experience of itch were assessed.

RESULTS

A total of 509 patients (210 male, median age: 64 years [52; 72]) were enrolled. Of these, 406 reported itch and CNPG lesions in the previous 7 days and qualified to complete the whole questionnaire. We recorded moderate to severe worst itch intensity scores in the previous 24 h. Scores were higher in patients with lower educational levels and those coming from Eastern or Southern Europe. Most patients experience itch often or always (71%) and report that their everyday life is negatively affected (53%). Itch intensity was considered to be the most burdensome aspect of the disease by 49% of the patients, followed by the visibility of skin lesions (21%) and bleeding of lesions (21%). The majority of patients was unaware of an underlying condition contributing to CNPG (64%), while psychiatric diseases were the conditions most often mentioned in association with CNPG (19%).

CONCLUSIONS

This multicentre cross-sectional study shows that itch is the dominant symptom in CNPG and reveals that the profile of the disease is similar throughout Europe.

摘要

背景

慢性结节性痒疹(CNPG)是一种以慢性瘙痒、长期搔抓行为和瘙痒性结节为特征的疾病。目前仍缺乏对该疾病的全面了解,尤其是其临床特征和对生活质量的影响。

目的

这项泛欧洲多中心横断面研究的目的是确定CNPG的临床特征,包括其相关负担。

方法

来自12个欧洲国家的15个中心招募了在中心就诊或使用中心自身数据库的CNPG患者。患者被要求以纸质或电子形式完成一份问卷。评估了人口统计学、当前合并症、基础疾病、瘙痒强度、其他感觉症状、生活质量、最高负担以及瘙痒的情感体验。

结果

共纳入509例患者(男性210例,中位年龄:64岁[52;72])。其中,406例在前7天报告有瘙痒和CNPG皮损,有资格完成整个问卷。我们记录了患者在前24小时内中度至重度的最严重瘙痒强度评分。教育程度较低以及来自东欧或南欧的患者评分更高。大多数患者经常或总是感到瘙痒(71%),并报告他们的日常生活受到负面影响(53%)。49%的患者认为瘙痒强度是该疾病最沉重的方面,其次是皮肤病变的可见性(21%)和病变出血(21%)。大多数患者不知道有导致CNPG的基础疾病(64%),而精神疾病是最常被提及与CNPG相关的疾病(19%)。

结论

这项多中心横断面研究表明,瘙痒是CNPG的主要症状,并揭示了该疾病在欧洲各地的特征相似。

相似文献

1
Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study.慢性结节性痒疹:临床特征与负担。一项欧洲横断面研究。
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2373-2383. doi: 10.1111/jdv.16309. Epub 2020 May 12.
2
Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis.单细胞 RNA 测序定义了慢性结节性瘙痒症和特应性皮炎之间的疾病特异性差异。
J Allergy Clin Immunol. 2023 Aug;152(2):420-435. doi: 10.1016/j.jaci.2023.04.019. Epub 2023 May 18.
3
Diagnostic and treatment algorithm for chronic nodular prurigo.慢性结节性痒疹的诊断和治疗方案。
J Am Acad Dermatol. 2020 Feb;82(2):460-468. doi: 10.1016/j.jaad.2019.07.022. Epub 2019 Jul 13.
4
Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.慢性瘙痒症,包括结节性瘙痒症:新的见解和治疗方法。
Am J Clin Dermatol. 2024 Jan;25(1):15-33. doi: 10.1007/s40257-023-00818-z. Epub 2023 Sep 17.
5
Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment.慢性结节性瘙痒症:发病机制和治疗的最新进展。
Int J Mol Sci. 2022 Oct 16;23(20):12390. doi: 10.3390/ijms232012390.
6
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.度普利尤单抗可改善慢性结节性痒疹成年患者的临床表现、症状和生活质量。
J Am Acad Dermatol. 2020 Jul;83(1):39-45. doi: 10.1016/j.jaad.2020.03.049. Epub 2020 Mar 27.
7
Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo.特应性皮炎和慢性结节性痒疹的白细胞介素谱分析。
Int J Mol Sci. 2024 Aug 2;25(15):8445. doi: 10.3390/ijms25158445.
8
Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment.325例慢性结节性痒疹患者的分析:临床特征、疾病负担及治疗过程
Acta Derm Venereol. 2020 Sep 30;100(16):adv00269. doi: 10.2340/00015555-3571.
9
The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: A comparative, retrospective, explorative statistical analysis of 4,484 patients in a real-world cohort.慢性瘙痒症的负担:与非皮损皮肤慢性瘙痒症患者相比,慢性瘙痒症患者的负担更大:一项真实世界队列中 4484 例患者的比较、回顾性、探索性统计分析。
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):738-743. doi: 10.1111/jdv.16929. Epub 2020 Nov 6.
10
Chronic Prurigo: Similar Clinical Profile and Burden Across Clinical Phenotypes.慢性痒疹:不同临床表型的相似临床特征与负担
Front Med (Lausanne). 2021 Jun 29;8:649332. doi: 10.3389/fmed.2021.649332. eCollection 2021.

引用本文的文献

1
Evaluation of routine care of prurigo nodularis in Germany: retrospective chart review study (ADVANCE PN).德国结节性痒疹常规护理评估:回顾性病历审查研究(ADVANCE PN)
J Dtsch Dermatol Ges. 2025 Jul;23(7):844-855. doi: 10.1111/ddg.15721. Epub 2025 Jun 8.
2
Content Validity and Psychometric Validation of an Adapted Version of the Subject Sleep Diary in Prurigo Nodularis.结节性痒疹患者睡眠日记改编版的内容效度和心理测量学验证
Dermatol Ther (Heidelb). 2025 Jun;15(6):1405-1426. doi: 10.1007/s13555-025-01406-1. Epub 2025 Apr 23.
3
Current Status of Prurigo Nodularis in Japan: A Retrospective Study Using a Health Insurance Claims Database.
日本结节性痒疹的现状:一项使用健康保险理赔数据库的回顾性研究
J Clin Med. 2025 Mar 11;14(6):1872. doi: 10.3390/jcm14061872.
4
Type 2 Inflammation and Its Role in Dermatologic Diseases.2型炎症及其在皮肤病中的作用。
Int J Dermatol. 2025 Jun;64(6):978-991. doi: 10.1111/ijd.17707. Epub 2025 Mar 22.
5
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.奈莫利单抗治疗中度至重度结节性痒疹患者的疗效和安全性:OLYMPIA 1随机临床3期试验
JAMA Dermatol. 2025 Feb 1;161(2):147-156. doi: 10.1001/jamadermatol.2024.4796.
6
Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.乌帕替尼治疗难治性结节性痒疹:一项前瞻性队列研究。
Allergy Asthma Immunol Res. 2024 Sep;16(5):546-554. doi: 10.4168/aair.2024.16.5.546.
7
Current clinical practice of prurigo nodularis in Japan: A cross-sectional web-survey among dermatologists.日本结节性痒疹的当前临床实践:皮肤科医生的横断面网络调查。
J Dermatol. 2025 Feb;52(2):348-352. doi: 10.1111/1346-8138.17400. Epub 2024 Sep 3.
8
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks.度普利尤单抗治疗结节性痒疹:长达84周的真实疗效
J Clin Med. 2024 Feb 2;13(3):878. doi: 10.3390/jcm13030878.
9
Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan.日本结节性痒疹患者的疾病负担和治疗满意度。
J Dermatol. 2024 Feb;51(2):223-233. doi: 10.1111/1346-8138.17045. Epub 2023 Dec 8.
10
[Chronic prurigo].[慢性瘙痒症]
Dermatologie (Heidelb). 2023 Nov;74(11):889-898. doi: 10.1007/s00105-023-05222-6. Epub 2023 Sep 18.